Currently, CD155/TIGIT has shown potential targeted therapeutic effects in a variety of malignancies, such as high-grade serous ovarian cancer (39) and head and neck squamous cell carcinoma (40). This evidence concerns the gene TIGIT and head and neck squamous cell carcinoma.